Last reviewed · How we verify
Codeine with acetaminophen
Codeine is an opioid agonist that binds to mu opioid receptors to reduce pain perception, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects.
Codeine is an opioid agonist that binds to mu opioid receptors to reduce pain perception, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects. Used for Mild to moderate pain in pediatric patients.
At a glance
| Generic name | Codeine with acetaminophen |
|---|---|
| Also known as | Capital® with Codeine Suspension, Acetaminophen and Codeine phosphate suspension |
| Sponsor | Children's Hospitals and Clinics of Minnesota |
| Drug class | Opioid analgesic combination |
| Target | Mu opioid receptor (codeine); COX enzymes (acetaminophen) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Codeine is a weak opioid that acts primarily as a mu receptor agonist in the central nervous system, reducing the transmission and perception of pain signals. Acetaminophen works through a separate mechanism by inhibiting cyclooxygenase (COX) enzymes and reducing prostaglandin production, providing complementary analgesia and fever reduction. The combination provides enhanced pain relief through dual mechanisms of action.
Approved indications
- Mild to moderate pain in pediatric patients
Common side effects
- Drowsiness
- Dizziness
- Constipation
- Nausea
- Respiratory depression
Key clinical trials
- Examining Analgesic Synergy and Efficacy in Trauma Care (PHASE4)
- Paracetamol With or Without Ketoprofen in the Management of Pain for Patients Receiving Brachytherapy (KETOCOL-1304) (PHASE2)
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
- Opioid-Free Pain Protocol After Shoulder Arthroplasty (PHASE4)
- Opioid-Sparing Joint Replacement (PHASE3)
- An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service (PHASE3)
- Celecoxib for ENT Pain Management (PHASE2)
- Post-Op Pain Control for Prophylactic Intramedullary Nailing. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |